Literature DB >> 18698083

Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort study.

Stefano Sacchi1, Luigi Marcheselli, Alessia Bari, Raffaella Marcheselli, Samantha Pozzi, Paolo G Gobbi, Francesco Angrilli, Maura Brugiatelli, Pellegrino Musto, Massimo Federico.   

Abstract

BACKGROUND: Improved treatment has increased the life expectancy of patients with non-Hodgkin's lymphoma, but few studies have addressed the issue of second cancer in patients treated for diffuse large B-cell lymphoma. The aims of this study were to determine the incidence and time free of second cancers in this subset of patients. DESIGN AND METHODS: We evaluated a cohort of 1280 patients with diffuse large B-cell lymphoma who were first treated between 1988 and 2003. We utilized the central database of the Gruppo Italiano Studio Linfomi, which includes data on demographics, clinical characteristics, laboratory parameters, treatment and follow-up of all patients with non-Hodgkin's lymphoma enrolled in clinical trials.
RESULTS: After a median follow-up of 51 months, 48 patients had developed a second cancer: 13 hematologic malignancies and 35 solid tumors. The overall standardized incidence ratio in our cohort (with a median age of 58 years) matched that of the general Italian population. The incidence ratio of second tumors was age related, and the age groups 20-39 and 40-59 years showed an increased risk. Overall, the cumulative incidence of second cancer was 8.2% at 15 years. A multivariate analysis showed that older age at the time of diagnosis of lymphoma had a negative influence on the time free of second tumors.
CONCLUSIONS: In our cohort, only young patients showed an increased incidence ratio of second malignancies, while the incidence ratio in patients aged over 59 years matched the incidence in the Italian general population. Demographics, baseline characteristics, laboratory parameters and treatment modalities did not have any significant impact on the incidence ratio of a second cancer.

Entities:  

Mesh:

Year:  2008        PMID: 18698083     DOI: 10.3324/haematol.12918

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  9 in total

Review 1.  Consolidative Radiation in DLBCL: Evidence-Based Recommendations.

Authors:  David C Hodgson; N George Mikhaeel
Journal:  Curr Oncol Rep       Date:  2015-11       Impact factor: 5.075

2.  Development of second primary malignancy in patients with non-Hodgkin lymphoma: a nationwide population-based study.

Authors:  Sheng-Hsuan Chien; Chia-Jen Liu; Ying-Chung Hong; Chung-Jen Teng; Yu-Wen Hu; Fan-Chen Ku; Chiu-Mei Yeh; Tzeon-Jye Chiou; Jyh-Pyng Gau; Cheng-Hwai Tzeng
Journal:  J Cancer Res Clin Oncol       Date:  2015-05-14       Impact factor: 4.553

3.  Radiation therapy improves survival in patients with testicular diffuse large B-cell lymphoma<sup/>.

Authors:  Jennifer C Ho; Bouthaina S Dabaja; Sarah A Milgrom; Grace L Smith; Jay P Reddy; Ali Mazloom; Ken H Young; Lijuan Deng; L Jeffrey Medeiros; Wenli Dong; Pamela K Allen; Therese Y Andraos; Nathan H Fowler; Loretta J Nastoupil; Yasuhiro Oki; Luis E Fayad; Francesco Turturro; Sattva S Neelapu; Jason Westin; Fredrick B Hagemeister; Maria Alma Rodriguez; Chelsea C Pinnix
Journal:  Leuk Lymphoma       Date:  2017-05-09

4.  Outcomes in lymphoma patients with obstructive jaundice: a cancer center experience.

Authors:  William A Ross; Chukwuma I Egwim; Michael J Wallace; Michael Wang; David C Madoff; Jeffrey H Lee
Journal:  Dig Dis Sci       Date:  2010-07-15       Impact factor: 3.199

5.  Second malignancies in patients with primary central nervous system lymphoma.

Authors:  Jun Wang; Jose S Pulido; Brian Patrick O'Neill; Patrick B Johnston
Journal:  Neuro Oncol       Date:  2014-06-19       Impact factor: 12.300

6.  Therapy-related myeloid neoplasm in non-hodgkin lymphoma survivors.

Authors:  Alessia Bari; Luigi Marcheselli; Raffaella Marcheselli; Eliana Valentina Liardo; Samantha Pozzi; Paola Ferri; Stefano Sacchi
Journal:  Mediterr J Hematol Infect Dis       Date:  2011-12-20       Impact factor: 2.576

7.  Myelodysplastic syndrome and acute myeloid leukemia after receipt of granulocyte colony-stimulating factors in older patients with non-Hodgkin lymphoma.

Authors:  Gregory S Calip; Kellyn M Moran; Karen I Sweiss; Pritesh R Patel; Zhaoju Wu; Sruthi Adimadhyam; Todd A Lee; Naomi Y Ko; John G Quigley; Brian C-H Chiu
Journal:  Cancer       Date:  2018-12-12       Impact factor: 6.921

8.  Quadri-lineage disease involving nodal B-cell marginal zone lymphoma, high-grade B-cell lymphoma, Kaposi's syndrome, and acute myeloid leukemia.

Authors:  Kamel Laribi; Habib Ghnaya; Pierre-Jean Mention; Hoel Rousset; Alix Baugier de Materre; Fabienne Pineau-Vincent; Catherine Truong; Delphine Bolle
Journal:  Clin Case Rep       Date:  2015-11-13

9.  Diffuse large B-cell lymphoma in very elderly patients over 80 years old: Incorporating consolidative radiation therapy into management decisions.

Authors:  Chelsea C Pinnix; Therese Y Andraos; Bouthaina Dabaja; Sarah Milgrom; Grace Smith; Dai Chihara; Andrea Ng; Luis E Fayad; Yasuhiro Oki; Sattva Neelapu; Jason Westin; M Alma Rodriguez; Loretta J Nastoupil
Journal:  Adv Radiat Oncol       Date:  2017-04-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.